Hansa is deploying Cradle's end-to-end platform to develop novel

汉莎正在部署 Cradle 的端到端平台，以开发新型

immunomodulatory therapies

免疫调节疗法

in autoimmune disease.

在自身免疫性疾病中。

AMSTERDAM

阿姆斯特丹

,

，

Oct. 1, 2026

2026年10月1日

/PRNewswire/ -- Hansa Biopharma AB (Nasdaq Stockholm: HNSA), a pioneer in treatments for rare IgG related immunologic conditions, today announced a partnership with Cradle, which builds the leading AI-driven protein design and engineering platform for biologics. Hansa will use Cradle's end-to-end platform across its discovery pipeline to design, optimize, and advance novel therapeutic candidates.

/美通社/ -- 罕见IgG相关免疫疾病治疗领域的先驱企业Hansa Biopharma AB（斯德哥尔摩纳斯达克股票代码：HNSA）今日宣布与Cradle建立合作伙伴关系。Cradle打造了领先的用于生物制剂的AI驱动蛋白质设计与工程平台。Hansa将在其发现管线中全面采用Cradle的一体化平台，以设计、优化并推进新型候选疗法。

Leveraging Cradle's AI driven protein engineering platform, the companies aim to accelerate the development of new therapeutics for patients with severe autoimmune diseases..

借助Cradle的AI驱动蛋白质工程平台，这些公司旨在加速为患有严重自身免疫性疾病的患者开发新疗法。

Hansa's lead product, imlifidase, is a first-in-class enzyme which is commercially available in Europe under the brand name Idefirix and is presently in FDA review with a PDUFA date in December for highly sensitized patients awaiting kidney transplant.

汉萨公司的领先产品imlifidase是一种首创酶类药物，已在欧洲以品牌名Idefirix上市销售，目前正接受美国食品药品监督管理局（FDA）审评，针对等待肾移植的高度致敏患者，其处方药用户费法案（PDUFA）裁决日期定于12月。

'

'

We evaluated several AI models and vendors and selected Cradle because it combines three capabilities we believe are essential for next-generation protein engineering: end-to-end support across the discovery pipeline, from hit identification onward; multi-parameter optimization across complex engineering objectives; and active learning from our own data to drive increasingly predictable outcomes.

我们评估了多款人工智能模型及供应商，最终选择了 Cradle，因为它融合了三项我们认为对下一代蛋白质工程至关重要的能力：覆盖从先导化合物鉴定开始的整个发现流程的端到端支持；针对复杂工程目标的多参数优化；以及基于自有数据的主动学习，以实现日益可预测的结果。

Each accelerates our lab-in-the-loop process. Cradle's platform enables Hansa scientists to design and engineer better therapeutic candidates, faster and with greater probability of success.

每一项都加速了我们的“实验室闭环”流程。Cradle的平台使Hansa的科学家能够以更快的速度和更高的成功概率，设计和优化更优质的候选治疗药物。

,' said Sofia Järnum, VP Head of Research and Early Development at Hansa.

汉萨公司研究与早期开发副总裁索菲亚·耶尔努姆表示。

The collaboration reflects Hansa's continued strategic investment in AI-powered drug discovery as it builds the next generation of its pipeline. Cradle's track record of delivering results with leading biopharmaceutical companies made it a natural partner as Hansa expands its use of AI across new discovery programs.

此次合作体现了汉莎生物在构建下一代产品管线过程中，对人工智能驱动药物研发的持续战略投入。Cradle 在与领先生物医药企业合作中屡创佳绩，因此随着汉莎生物将人工智能应用拓展至新的研发项目，Cradle 成为其天然的合作伙伴。

The partnership reflects a growing shift toward unified AI platforms that combine candidate generation, optimization, and continuous learning from experimental data in a single workflow. According to Cradle, customers report development timelines up to 18 months faster, suggesting translation into significant R&D savings per clinical candidate..

此次合作反映出行业正日益转向统一的AI平台，这些平台将候选分子生成、优化以及基于实验数据的持续学习整合到单一工作流中。据Cradle称，客户报告的开发周期缩短了多达18个月，这意味着每个临床候选药物都能显著节省研发成本。

'

'

The future of multimodality therapeutics engineering isn't about spending more AI tokens or navigating a stable of models. It's about empowering scientists with a platform that learns alongside them, while enabling them to apply their unique human expertise to solve complex molecular challenges at scale, with speed and precision.

多模态治疗工程的未来，不在于消耗更多的AI算力或在众多模型中周旋。其核心在于为科学家提供一个能够与他们共同学习的平台，使他们能够凭借独特的人类专业知识，以规模化、高速度和精准度的方式解决复杂的分子难题。

,' said Stef van Grieken, CEO and Co-Founder of Cradle. '

Cradle 首席执行官兼联合创始人 Stef van Grieken 表示：“

We're excited to partner with Hansa on their mission to accelerate the discovery and development of novel, high quality therapeutics for patients suffering from rare and severe autoimmune disorders

我们很高兴与 Hansa 合作，支持其使命，加速为患有罕见且严重自身免疫性疾病的患者发现并开发新型高质量疗法。

.'

。'

About Hansa Biopharma

关于汉莎生物制药

Hansa Biopharma AB is a pioneering commercial-stage biopharmaceutical company developing and commercializing novel immunomodulatory therapies to transform care for patients with acute or complex immune disorders. Hansa's proprietary IgG-cleaving enzyme technology platform addresses serious unmet medical needs in transplantation, gene therapy and autoimmune diseases.

汉莎生物制药公司（Hansa Biopharma AB）是一家处于商业化阶段的先锋生物制药企业，致力于开发和商业化新型免疫调节疗法，以变革急性或复杂免疫疾病患者的治疗模式。汉莎公司专有的IgG裂解酶技术平台旨在满足移植、基因治疗和自身免疫性疾病领域尚未被满足的重大医疗需求。

The company's portfolio includes imlifidase, a first-in-class immunoglobulin G (IgG) antibody-cleaving enzyme therapy, which has been shown to enable kidney transplantation in highly sensitized patients, and HNSA-5487, a next-generation IgG-cleaving molecule that will be developed for Guillain-Barré Syndrome (GBS).

该公司的产品组合包括imlifidase，这是一种首创的免疫球蛋白G（IgG）抗体切割酶疗法，已证明能使高度致敏患者进行肾移植；以及HNSA-5487，这是一种下一代IgG切割分子，将用于开发治疗吉兰-巴雷综合征（GBS）。

Hansa Biopharma is based in Lund, Sweden, and has operations in Europe and the U.S. The company is listed on Nasdaq Stockholm under the ticker HNSA. Find out more at .

汉莎生物制药公司总部位于瑞典隆德，在欧洲和美国开展业务。该公司在纳斯达克斯德哥尔摩交易所上市，股票代码为HNSA。欲了解更多信息，请访问。

www.hansabiopharma.com

www.hansabiopharma.com

and follow us on LinkedIn.

并在 LinkedIn 上关注我们。

©2026 Hansa Biopharma AB. Hansa Biopharma, the beacon logo, IDEFIRIX, and IDEFIRIX flower logo are trademarks of Hansa Biopharma AB, Lund, Sweden. All rights reserved.

©2026 Hansa Biopharma AB。Hansa Biopharma、灯塔标志、IDEFIRIX 以及 IDEFIRIX 花朵标志均为瑞典隆德 Hansa Biopharma AB 的商标。版权所有。

About Cradle

关于 Cradle

Cradle's mission is to enable every scientist to turn today's impossible cures, foods, and materials into tomorrow's ordinary. Cradle's end-to-end protein engineering platform helps scientists intentionally engineer biologics across the full design-to-candidate lifecycle, bringing AI-driven molecular engineering, active learning from experimental data, and multi-property optimization together in a single system.

Cradle 的使命是让每一位科学家都能将当今看似不可能的疗法、食品和材料转化为明天的寻常之物。Cradle 提供端到端的蛋白质工程平台，帮助科学家在从设计到候选物的完整生命周期中有意地开发生物制品，将人工智能驱动的分子工程、基于实验数据的主动学习以及多属性优化整合于一个统一的系统中。

Today, the platform is trusted by many of the biggest names in global pharmaceutical, industrial bio, agriculture and consumer goods across more than 80 active R&D programs. Cradle is based in Amsterdam, The Netherlands; Zürich, Switzerland and the United States with a team of machine learning and biotech research experts with deep industry experience from many of the world's leading technology and biotech companies.

如今，该平台已赢得全球制药、工业生物技术、农业和消费品领域众多顶尖企业的信赖，支持着80多个活跃的研发项目。Cradle总部位于荷兰阿姆斯特丹、瑞士苏黎世和美国，拥有一支由机器学习和生物技术研究专家组成的团队，这些专家来自全球领先的科技和生物技术公司，具备深厚的行业经验。

Cradle is backed by IVP as well as Index Ventures and Kindred Capital. For more information, visit cradle.bio..

Cradle 由 IVP、Index Ventures 和 Kindred Capital 支持。欲了解更多信息，请访问 cradle.bio。

SOURCE Cradle; Hansa Biopharma AB

来源：Cradle；Hansa Biopharma AB

21

二十一

%

百分比

more press release views with

更多新闻稿浏览量，附带

Request a Demo

申请演示